|
|
Blood, 15 November 2007, Vol. 110, No. 10, pp. 3662-3672.
Prepublished online as a Blood First Edition Paper on July 25, 2007; DOI 10.1182/blood-2007-02-073213.
 Previous Article | Next Article 
Submitted February 8, 2007
Accepted July 13, 2007
Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during taxol treatment
Katja Janssen, Stephan Pohlmann, Reiner U. Janicke, Klaus Schulze-Osthoff, and Ute Fischer*
Institute of Molecular Medicine, Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany
* Corresponding author; email: ute.fischer{at}uni-duesseldorf.de.
Taxane derivatives such as taxol (paclitaxel) elicit their antitumor effects at least in part by induction of apoptosis, but the underlying mechanisms are incompletely understood. Here, we employed different cellular models with deficiencies in key regulators of apoptosis to elucidate the mechanism of taxol-induced cell death. Apoptosis by taxol was reported to depend on the activation of the initiator caspase-10, however, we clearly demonstrate that taxol kills murine embryonic fibroblasts (MEFs) devoid of caspase-10 as well as human tumor cell lines deficient in caspase-10, -8 or FADD. In contrast, the lack of Apaf-1 or caspase-9, key regulators of the mitochondrial pathway, not only entirely protected against taxol-induced apoptosis but could even confer clonogenic survival, depending on the cell type and drug concentration. Thus, taxol triggers apoptosis not through caspase-10, but via caspase-9 activation at the apoptosome. This conclusion is supported by the fact that Bcl-2-overexpressing cells and Bax/Bak doubly deficient MEFs were entirely resistant to taxol-induced apoptosis. Interestingly, also the single knockout of Bim or Bax, but not that of Bak or Bid conferred partial resistance, suggesting a particular role of these mediators in the cell death pathway activated by taxol.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Taxol therapy revisited
- Shida Yousefi and Hans-Uwe Simon
Blood 2007 110: 3492.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K. Janssen, S. Horn, M. T. Niemann, P. T. Daniel, K. Schulze-Osthoff, and U. Fischer
Inhibition of the ER Ca2+ pump forces multidrug-resistant cells deficient in Bak and Bax into necrosis
J. Cell Sci.,
December 15, 2009;
122(24):
4481 - 4491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lartigue, Y. Kushnareva, Y. Seong, H. Lin, B. Faustin, and D. D. Newmeyer
Caspase-independent Mitochondrial Cell Death Results from Loss of Respiration, Not Cytotoxic Protein Release
Mol. Biol. Cell,
December 1, 2009;
20(23):
4871 - 4884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Mol. Cancer Ther.,
August 1, 2009;
8(8):
2086 - 2095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ellis, M. Bots, R. K. Lindemann, J. E. Bolden, A. Newbold, L. A. Cluse, C. L. Scott, A. Strasser, P. Atadja, S. W. Lowe, et al.
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
Blood,
July 9, 2009;
114(2):
380 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
